• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

不同年龄段 COVID-19 患者的 SARS-CoV-2 特异性抗体反应特征。

SARS-CoV-2-specific antibody response characteristics in COVID-19 patients of different ages.

机构信息

Key Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education, Fuzhou 350122, China.

Shanghai Center for Systems Biomedicine, Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Jiao Tong University, Shanghai 200240, China.

出版信息

Acta Biochim Biophys Sin (Shanghai). 2022 Apr 25;54(4):556-564. doi: 10.3724/abbs.2022014.

DOI:10.3724/abbs.2022014
PMID:35607955
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9828714/
Abstract

Age has been found to be one of the main risk factors for the severity and outcome of COVID-19. However, differences in SARS-CoV-2 specific antibody responses among COVID-19 patients of different age groups remain largely unknown. In this study, we analyzed the IgG/IgM responses to 21 SARS-CoV-2 proteins and 197 peptides that fully cover the spike protein against 731 sera collected from 731 COVID-19 patients aged from 1 to We show that there is no overall difference in SARS-CoV-2 antibody responses in COVID-19 patients in the 4 age groups. By antibody response landscape maps, we find that the IgG response profiles of SARS-CoV-2 proteins are positively correlated with age. The S protein linear epitope map shows that the immunogenicity of the S-protein peptides is related to peptide sequence, disease severity and age of the COVID-19 patients. Furthermore, the enrichment analysis indicates that low S1 IgG responses are enriched in patients aged <50 and high S1 IgG responses are enriched in mild COVID-19 patients aged >60. In addition, high responses of non-structural/accessory proteins are enriched in severe COVID-19 patients aged >70. These results suggest the distinct immune response of IgG/IgM to each SARS-CoV-2 protein in patients of different age, which may facilitate a deeper understanding of the immune responses in COVID-19 patients.

摘要

年龄被发现是 COVID-19 严重程度和结局的主要危险因素之一。然而，不同年龄组 COVID-19 患者中 SARS-CoV-2 特异性抗体反应的差异在很大程度上尚不清楚。在这项研究中，我们分析了 731 例 COVID-19 患者的 731 份血清中针对 21 种 SARS-CoV-2 蛋白和 197 个全长刺突蛋白肽的 IgG/IgM 反应，这些患者的年龄从 1 岁到 101 岁不等。我们表明，4 个年龄组的 COVID-19 患者中 SARS-CoV-2 抗体反应没有总体差异。通过抗体反应图谱，我们发现 SARS-CoV-2 蛋白的 IgG 反应谱与年龄呈正相关。S 蛋白线性表位图谱表明，S 蛋白肽的免疫原性与肽序列、疾病严重程度和 COVID-19 患者的年龄有关。此外，富集分析表明，S1 区 IgG 低反应在年龄<50 岁的患者中富集，而 S1 区 IgG 高反应在年龄>60 岁的轻症 COVID-19 患者中富集。此外，高龄 (>70 岁) 的严重 COVID-19 患者中，非结构/辅助蛋白的高反应富集。这些结果表明，不同年龄组患者对每种 SARS-CoV-2 蛋白的 IgG/IgM 免疫反应不同，这可能有助于更深入地了解 COVID-19 患者的免疫反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b67/9828714/54e9594437a8/ABBS-2021-568-t5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b67/9828714/91536b2188a8/ABBS-2021-568-t1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b67/9828714/da3d822f3b9e/ABBS-2021-568-t2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b67/9828714/7bd4956fe4cb/ABBS-2021-568-t3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b67/9828714/bcf6c885dda6/ABBS-2021-568-t4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b67/9828714/54e9594437a8/ABBS-2021-568-t5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b67/9828714/91536b2188a8/ABBS-2021-568-t1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b67/9828714/da3d822f3b9e/ABBS-2021-568-t2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b67/9828714/7bd4956fe4cb/ABBS-2021-568-t3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b67/9828714/bcf6c885dda6/ABBS-2021-568-t4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b67/9828714/54e9594437a8/ABBS-2021-568-t5.jpg

相似文献

1
SARS-CoV-2-specific antibody response characteristics in COVID-19 patients of different ages.不同年龄段 COVID-19 患者的 SARS-CoV-2 特异性抗体反应特征。
Acta Biochim Biophys Sin (Shanghai). 2022 Apr 25;54(4):556-564. doi: 10.3724/abbs.2022014.
2
Antibody landscape against SARS-CoV-2 reveals significant differences between non-structural/accessory and structural proteins.抗体对 SARS-CoV-2 的反应揭示了非结构/辅助蛋白和结构蛋白之间的显著差异。
Cell Rep. 2021 Jul 13;36(2):109391. doi: 10.1016/j.celrep.2021.109391. Epub 2021 Jun 26.
3
Over 1-year duration and age difference of SARS-CoV-2 antibodies in convalescent COVID-19 patients.SARS-CoV-2 抗体在康复期 COVID-19 患者中的 1 年以上持续时间和年龄差异。
J Med Virol. 2021 Dec;93(12):6506-6511. doi: 10.1002/jmv.27152. Epub 2021 Jul 26.
4
Evaluation of Spike Protein Epitopes by Assessing the Dynamics of Humoral Immune Responses in Moderate COVID-19.评估刺突蛋白表位：评估中度 COVID-19 中体液免疫反应的动态变化。
Front Immunol. 2022 Mar 18;13:770982. doi: 10.3389/fimmu.2022.770982. eCollection 2022.
5
Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19.SARS-CoV-2 感染和 COVID-19 康复过程中抗 SARS-CoV-2 抗体的动态变化。
Nat Commun. 2020 Nov 27;11(1):6044. doi: 10.1038/s41467-020-19943-y.
6
Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays.采用微阵列和其他 12 种免疫分析法评估急性 SARS-CoV-2 感染中 S1、S2 和 NCP 特异性 IgM、IgA 和 IgG 抗体的动力学。
J Clin Microbiol. 2021 Apr 20;59(5). doi: 10.1128/JCM.02890-20.
7
Validation of a new automated chemiluminescent anti-SARS-CoV-2 IgM and IgG antibody assay system detecting both N and S proteins in Japan.日本一种新型自动化化学发光抗SARS-CoV-2 IgM和IgG抗体检测系统的验证，该系统可同时检测N蛋白和S蛋白。
PLoS One. 2021 Mar 4;16(3):e0247711. doi: 10.1371/journal.pone.0247711. eCollection 2021.
8
Monitoring Specific IgM and IgG Production Among Severe COVID-19 Patients Using Qualitative and Quantitative Immunodiagnostic Assays: A Retrospective Cohort Study.利用定性和定量免疫诊断检测监测重症 COVID-19 患者的特异性 IgM 和 IgG 产生：一项回顾性队列研究。
Front Immunol. 2021 Sep 3;12:705441. doi: 10.3389/fimmu.2021.705441. eCollection 2021.
9
Evaluation of serum IgM and IgG antibodies in COVID-19 patients by enzyme linked immunosorbent assay.酶联免疫吸附试验评价 COVID-19 患者血清 IgM 和 IgG 抗体。
J Med Virol. 2021 May;93(5):2857-2866. doi: 10.1002/jmv.26741. Epub 2021 Mar 1.
10
Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.在真实环境中评估灭活 COVID-19 疫苗诱导的 SARS-CoV-2 特异性体液和细胞免疫应答的特征。
Front Immunol. 2021 Dec 22;12:802858. doi: 10.3389/fimmu.2021.802858. eCollection 2021.

引用本文的文献

1
Kinetics of specific anti-SARS-CoV-2 IgM, IgA, and IgG responses during the first 12 months after SARS-CoV-2 infection: A prospective longitudinal study.SARS-CoV-2 感染后 12 个月内特异性抗 SARS-CoV-2 IgM、IgA 和 IgG 反应的动力学：一项前瞻性纵向研究。
PLoS One. 2023 Jul 12;18(7):e0288557. doi: 10.1371/journal.pone.0288557. eCollection 2023.

本文引用的文献

1
COVID-ONE-hi: The One-stop Database for COVID-19-specific Humoral Immunity and Clinical Parameters.COVID-ONE-hi：用于 COVID-19 特异性体液免疫和临床参数的一站式数据库。
Genomics Proteomics Bioinformatics. 2021 Oct;19(5):669-678. doi: 10.1016/j.gpb.2021.09.006. Epub 2021 Nov 5.
2
Comparison of SARS-CoV-2 Antibody Response by Age Among Recipients of the BNT162b2 vs the mRNA-1273 Vaccine.BNT162b2 与 mRNA-1273 疫苗接种者的年龄与 SARS-CoV-2 抗体反应比较。
JAMA Netw Open. 2021 Sep 1;4(9):e2124331. doi: 10.1001/jamanetworkopen.2021.24331.
3
Systematic profiling of SARS-CoV-2-specific IgG responses elicited by an inactivated virus vaccine identifies peptides and proteins for predicting vaccination efficacy.
对灭活病毒疫苗引发的SARS-CoV-2特异性IgG反应进行系统分析，可鉴定出用于预测疫苗效力的肽段和蛋白质。
Cell Discov. 2021 Aug 17;7(1):67. doi: 10.1038/s41421-021-00309-7.
4
SARS-CoV-2 spike linear epitope scanning via a peptide microarray through sera profiling.通过血清分析的肽微阵列对 SARS-CoV-2 刺突线性表位进行扫描。
STAR Protoc. 2021 Sep 17;2(3):100707. doi: 10.1016/j.xpro.2021.100707. Epub 2021 Jul 10.
5
SARS-CoV-2 Accessory Proteins in Viral Pathogenesis: Knowns and Unknowns.SARS-CoV-2 辅助蛋白在病毒发病机制中的作用：已知和未知。
Front Immunol. 2021 Jul 7;12:708264. doi: 10.3389/fimmu.2021.708264. eCollection 2021.
6
Antibody landscape against SARS-CoV-2 reveals significant differences between non-structural/accessory and structural proteins.抗体对 SARS-CoV-2 的反应揭示了非结构/辅助蛋白和结构蛋白之间的显著差异。
Cell Rep. 2021 Jul 13;36(2):109391. doi: 10.1016/j.celrep.2021.109391. Epub 2021 Jun 26.
7
Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19.SARS-CoV-2 的结构蛋白和非结构蛋白及其在 COVID-19 中的治疗靶点的作用。
Cells. 2021 Apr 6;10(4):821. doi: 10.3390/cells10040821.
8
Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients.来自 1051 名 COVID-19 患者的 SARS-CoV-2 刺突蛋白线性表位图谱。
Cell Rep. 2021 Mar 30;34(13):108915. doi: 10.1016/j.celrep.2021.108915. Epub 2021 Mar 12.
9
SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19.SARS-CoV-2 感染会在有症状的 COVID-19 康复患者中诱导出持续的体液免疫反应。
Nat Commun. 2021 Mar 22;12(1):1813. doi: 10.1038/s41467-021-22034-1.
10
Association of Age With SARS-CoV-2 Antibody Response.年龄与 SARS-CoV-2 抗体反应的关系。
JAMA Netw Open. 2021 Mar 1;4(3):e214302. doi: 10.1001/jamanetworkopen.2021.4302.